Welcome!

News Feed Item

Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer

VIENNA, September 3, 2014 /PRNewswire/ --

New US Subsidiary to be located in the Philadelphia Area 

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative pathogens, today announced the appointment of Dr Colin Broom as Chief Executive Officer (CEO). Current CEO Ralf Schmid will remain a member of the executive management team and move to the role of Chief Operating Officer (COO) and Chief Financial Officer (CFO). The company also announced the establishment of a US subsidiary, based in Philadelphia, Pennsylvania, where the clinical development team will be located. All other activities will remain in Vienna. Nabriva plans to take its lead product lefamulin (BC‑3781) into late stage development in community-acquired bacterial pneumonia and advance its pipeline of Extended Spectrum Pleuromutilins (ESP), active against gram-negative bacteria.

Dr Denise Pollard-Knight, Chairman of the Supervisory Board of Nabriva, commented on the appointment: "We welcome Colin to Nabriva and are delighted to announce the opening of our US subsidiary. Colin's track record and experience will enable us to maximise the potential in Nabriva's pipeline. The increasing interest in the development of new antibiotics and a favourable funding environment for biotech companies in the US provide a great opportunity to position the company for significant growth in the future.

"I would like to take this opportunity to thank Ralf Schmid, the current CEO who is assuming the roles of COO and CFO. Ralf has been instrumental in establishing Nabriva and leading us to this important stage, and will in his new role head the Austrian site and continue to play a key role in the company's future development."

Dr Broom, newly appointed Chief Executive Officer of Nabriva, added: "New antibiotic development is one of the most important priorities in medicine as we see increasing resistance to currently available drugs.  Nabriva is one of a few development stage companies with a truly novel antibiotic product ready for phase 3 studies in an area of significant unmet medical need, and with a clear development path to potential approval. I am very excited to join Nabriva at this stage and look forward to working with the highly experienced board and management team on building a patient-centric global biopharmaceutical company. My immediate attention is focussed on establishing a world-class clinical development team in the Philadelphia area."

Dr Broom has worked in biopharmaceutical drug development and commercialization for 30 years. Most recently he served as Chief Scientific Officer at ViroPharma, Inc., which was acquired by Shire plc for $4.2bn in January 2014. Prior development roles included senior positions at Amgen, Hoechst Marion Roussel (now Sanofi), SmithKline Beecham and Glaxo (now GlaxoSmithKline). Dr Broom also serves on the board of NPS Pharmaceuticals.

Dr Broom holds a Bachelor of Science degree in pharmacology from University College, London, and a Bachelor of Medicine and Bachelor of Surgery degree from St. George's Hospital Medical School, London. He is a Member of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine of the UK Colleges of Physicians.

Notes to editors 

About Nabriva Therapeutics AG  

Nabriva Therapeutics is a biotechnology company focused on developing a new class of antibiotics, the pleuromutilins, for the treatment of patients with serious infections caused by multi-drug resistant pathogens. Nabriva's world-class medicinal chemistry expertise has achieved an industry first with the development of both intravenously administered and orally available pleuromutilins that are therefore ideal for i.v. to oral switch therapy.

Nabriva's lead product lefamulin (BC‑3781) is about to enter Phase 3 clinical studies. Due to its broad spectrum, oral and i.v. formulations, and a favourable safety profile, lefamulin is the first of a new class of antibiotics ideally positioned for the treatment of community-acquired bacterial pneumonia (CABP), plus hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), as well as acute bacterial skin and skin structure infections (ABSSSI), with potential in several other indications (sexually transmitted infections including MDR gonorrhoea; osteomyelitis) including paediatric use.

Nabriva's preclinical program, the Extended Spectrum Pleuromutilins (ESPs) expands the activity of pleuromutilins to include major enteric Gram-negative pathogens such as E. coli and K. pneumoniae. The targeted indications for the ESP extend beyond the current use of the first-generation pleuromutilins, thereby filling important gaps in treatment options of both marketed antibiotics and compounds in development.

For further information, please contact: 

Nabriva Therapeutics AG
Dr Colin Broom, Chief Executive Officer
Tel: +43(0)1-740-930
Email: [email protected]

Hume Brophy
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44(0)2034405654
Email: [email protected]


 

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"I think DevOps is now a rambunctious teenager – it’s starting to get a mind of its own, wanting to get its own things but it still needs some adult supervision," explained Thomas Hooker, VP of marketing at CollabNet, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We are still a relatively small software house and we are focusing on certain industries like FinTech, med tech, energy and utilities. We help our customers with their digital transformation," noted Piotr Stawinski, Founder and CEO of EARP Integration, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Chris Matthieu is the President & CEO of Computes, inc. He brings 30 years of experience in development and launches of disruptive technologies to create new market opportunities as well as enhance enterprise product portfolios with emerging technologies. His most recent venture was Octoblu, a cross-protocol Internet of Things (IoT) mesh network platform, acquired by Citrix. Prior to co-founding Octoblu, Chris was founder of Nodester, an open-source Node.JS PaaS which was acquired by AppFog and ...
The Founder of NostaLab and a member of the Google Health Advisory Board, John is a unique combination of strategic thinker, marketer and entrepreneur. His career was built on the "science of advertising" combining strategy, creativity and marketing for industry-leading results. Combined with his ability to communicate complicated scientific concepts in a way that consumers and scientists alike can appreciate, John is a sought-after speaker for conferences on the forefront of healthcare science,...
"We focus on SAP workloads because they are among the most powerful but somewhat challenging workloads out there to take into public cloud," explained Swen Conrad, CEO of Ocean9, Inc., in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"The Striim platform is a full end-to-end streaming integration and analytics platform that is middleware that covers a lot of different use cases," explained Steve Wilkes, Founder and CTO at Striim, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.
Your job is mostly boring. Many of the IT operations tasks you perform on a day-to-day basis are repetitive and dull. Utilizing automation can improve your work life, automating away the drudgery and embracing the passion for technology that got you started in the first place. In this presentation, I'll talk about what automation is, and how to approach implementing it in the context of IT Operations. Ned will discuss keys to success in the long term and include practical real-world examples. Ge...
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
"NetApp's vision is how we help organizations manage data - delivering the right data in the right place, in the right time, to the people who need it, and doing it agnostic to what the platform is," explained Josh Atwell, Developer Advocate for NetApp, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science," is responsible for setting the strategy and defining the Big Data service offerings and capabilities for EMC Global Services Big Data Practice. As the CTO for the Big Data Practice, he is responsible for working with organizations to help them identify where and how to start their big data journeys. He's written several white papers, is an avid blogge...
When building large, cloud-based applications that operate at a high scale, it's important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. "Fly two mistakes high" is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Le...
When talking IoT we often focus on the devices, the sensors, the hardware itself. The new smart appliances, the new smart or self-driving cars (which are amalgamations of many ‘things'). When we are looking at the world of IoT, we should take a step back, look at the big picture. What value are these devices providing. IoT is not about the devices, its about the data consumed and generated. The devices are tools, mechanisms, conduits. This paper discusses the considerations when dealing with the...